Unerwünschte Arzneimittelwirkungen (UAW) sind in der Augenheilkunde ein häufiges Ereignis. Hinzu kommt der große Bereich der Arzneimittelwechselwirkungen. Im vorliegenden Beitrag kann nicht das gesamte Spektrum möglicher UAW angesprochen werden, vielmehr werden Schwerpunkte (z. B. Glaukommittel und systemisch eingesetzte Therapeutika) und aktuelle Aspekte hervorgehoben. Hierzu gehören u. a.:
-
Wechselwirkungen zwischen Glaukommitteln und oralen Antihypertensiva
-
intraoperatives Floppy-Iris-Syndrom
-
intravitreale okuläre Medikamentenapplikation
-
UAW systemischer Medikamente an der Netzhaut und am N. opticus
Literatur
-
1
Adelman R A, Zheng Q, Mayer H R.
Persistent ocular hypertension following intravitreal bevacizumab and renibizumab injections.
J Ocul Pharmacol Ther.
2010;
105-110
-
2
Alm A, Grierson I, Shields M B.
Side effects associated with prostaglandin analog therapy.
Surv Ophthalmol.
2008;
53
93-105
-
3
Al-Shahwan S, Al-Torbak A A, Turkmani S et al.
Side-effect profile of brimonidine tartrate in children.
Ophthalmology.
2005;
112
2143
-
4
Aragona P, Di Pietro R.
Is it safe to use topical NSAIDs for corneal sensitivity in Sjögren's syndrome patients?.
Expert Opin Drug Saf.
2007;
6
33-43
-
5
Arranz Marquez E, Teus Guezala M A, Canseco Gonzalez F.
Respiratory effects of chronic therapy with latanoprost in patients with chronic obstructive pulmonary disease (COPD).
Arch Soc Esp Oftalmol.
2002;
77
553-558
-
6
Baba T, Kubota-Taniai M, Kitahashi M et al.
Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation.
Br J Ophthalmol.
2010;
94
864-870
-
7
Cardascia N, Boscia F, Furino C et al.
Gentamicin-induced macular infarction in transconjunctival sutureless 25-gauge vitrectomy.
Int Ophthalmol.
2008;
28
383-385
-
8
Casuccio A, Cillino G, Pavone C et al.
Pharmacologic pupil dilation as a predicitve test for the risk for intraoperative floppy-iris syndrome.
J Cataract Refract Surg.
2011;
37
1447-1454
-
9
Chang D F, Campbell J R.
Intraoperative floppy iris syndrome associated with tamsulosin.
J Cataract Refract Surg.
2005;
31
664-673
-
10
Coppens G, Stalmans I, Zeyen T et al.
The safety and efficacy of glaucoma medication in the pediatric population.
J Pediatr Ophthalmol Strabismus.
2009;
46
12-18
-
11
Ebenezer D, Thorne J E.
Recent advances in mucous membrane pemphigoid.
Curr Opin Ophthalmol.
2008;
19
292-297
-
12
Gianni L, Panzini I, Li S et al.
International Breast Cancer Study Group. Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials.
Cancer.
2006;
106
505-513
-
13
Guillet V, Chevrollier A, Cassereau J et al.
Ethambutol-induced optic neuropathy linked to OPA1 mutation and mitochondrial toxicity.
Mitochondrion.
2010;
10
115-124
-
14
Haller J A, Bandello F, Belfort jr. R et al.
Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion. Twelve-months study results.
Ophthalmology.
2011;
(Epub ahead of print)
-
15
Jonas J B.
Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases.
Acta Ophthalmol Scand.
2005;
83
645-663
-
16
Kellner S, Weinitz S, Kellner U.
Spectral domain optical coherence tomography detects early stages of chloroquine retinopathy similar to multifocal electroretinography, fundus autofluorescence and near-infrared autofluorescence.
Br J Ophthalmol.
2009;
93
1444-1447
-
17
Marmor M F, Kellner U, Lai T Y Y for the American Academy of Ophthalmology et al.
Revised recommendations on screening for chloroquine and hydroxchloroquine retinopathy.
Ophthalmology.
2011;
118
415-422
-
18
Menon V, Jain D, Saxena R et al.
Prospective evaluation of visual function for early detection of ethambutol toxicity.
Br J Ophthalmol.
2009;
93
1251-1254
-
19 Mielke J. Intraokularer Druck. In: Schlote T, Kellner U, Hrsg. Unerwünschte Arzneimittelwirkungen in der Augenheilkunde. Stuttgart: Georg Thieme Verlag; 2011: 85
-
20
Payne J F, Bergstrom C, Yan J et al.
Residual triamcinolone acetonide sequested in the fovea after macular hole repair.
Retina.
2011;
31
148-53
-
21
Purvin V, Kawasaki A, Borruat F X.
Optic neuropathy in patients using amiodarone.
Arch Ophthalmol.
2006;
124
696-701
-
22
Ramdas W D, van der Velde N, van der Cammen T F et al.
Evaluation of risk of falls and orthostatic hypotension in older long-term topical beta-blocker users.
Graefes Arch Clin Exp Ophthalmol.
2009;
247
1235-1241
-
23
Reviglio V E, Rana T S, Li Q J et al.
Effects of topical nonsteroidal antiinflammatory drugs on the expression of matrix metalloproteinases in the cornea.
J Cataract Refract Surg.
2003;
29
989-997
-
24
Rinalduzzi S, Cipriani A M, Accornero N.
Topiramate and visual loss in a patient carrying a Leber hereditary optic neuropathy mutation.
Neurol Sci.
2011;
(Epub ahead of print)
-
25
Salim S, Shields M B.
Glaucoma and systemic diseases.
Surv Ophthalmol.
2010;
55
64-77
-
26
Santanaella RM, Fraunfelder FW. Ocular adverse effects associated with systemic medications.
Drugs.
2007;
67
75-93
-
27 Schlote T, Kellner U Hrsg.. Unerwünschte Arzneimittelwirkungen in der Augenheilkunde. 1. Aufl. Stuttgart: Georg Thieme Verlag; 2011: 4
-
28
Schlote T, Kellner U.
Nebenwirkungen von Medikamenten am Auge.
Klin Monatsbl Augenheilkd.
2009;
226
R173-R186
-
29
Teseng J J, Vance S K, Della Torre K E et al.
Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
J Glaucoma.
2011;
(Epub ahead of print)
-
30
Urtti A, Salminen L.
Minimizing systemic absorption of topically administered ophthalmic drugs.
Surv Ophthalmol.
1993;
37
435-456
-
31
Vanhaesebrouck S, Cossey V, Cosaert K et al.
Cardiorespiratory depression and hyperglycemia after unintentional ingestion of brimonidine in a neonate.
Eur J Ophthalmol.
2009;
19
694-695
-
32
Wright T M, Freedman S F.
Exposure to topical apraclonidine in children with glaucoma.
J Glaucoma.
2009;
18
395-398
Prof. Dr. med. T. Schlote
Tagesklinik Ambimed Basel
Klingentalstrasse 9
CH-4057 Basel
Schweiz
Phone: 00 41-61/3 22-13 57
Fax: 00 41-61/3 83-14 48
Email: praxis.schlote@bluewin.ch
